Creating next generation therapies to cure neurological diseases

Changing the Outlook on Glioblastoma

In GBM, traditional therapies address the proliferative tumor — impacting quality of life, but failing to meaningfully extend survival.

With PNM-201, we're targeting the right cell population. Recurrence is driven by GBM tumor stem cells that invade into healthy brain tissue, converting into new tumors. These TSC's uniquely express the IL13a2 receptor. PNM-201 selectively targets and kills these tumor stem cells, delivering a potent cytotoxic payload.